SQZ Biotechnologies IPO

10/30/2020

IPO

$70,400,000

Management says it will use the net proceeds from the IPO as follows:approximately $75 million to advance the clinical development of SQZ-PBMC-HPV, from our SQZ APC platform, including completing our ongoing Phase 1 clinical trial in patients with locally advanced and metastatic HPV+ tumors and commencing enrollment for SQZ-PBMC-HPV as a combination therapy;approximately $25 million to initiate our first clinical trial of SQZ-AAC-HPV for the treatment of HPV+ tumors and to advance the development of additional product candidates using our SQZ AAC platform; andthe remainder to advance the development of other product candidates across our pipeline, including additional product candidates in oncology and infectious disease using our SQZ APC platform and product candidates in tolerance using our SQZ TAC platform, as well as for working capital and other general corporate purposes.

Publicly-held

Biopharmaceutical

200 Arsenal Yards Blvd.
Watertown, MA 02472
USA

SQZ Biotechnologies (Nasdaq: SQZ). Many promising therapeutic modalities have limited clinical efficacy due to the challenges of delivering molecules into cells. SQZ Biotech seeks to address this fundamental problem by developing its CellSqueeze platform for use in drug discovery and clinical applications.